Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease: comment on the article by Khanna et al.

Bredemeier, Markus

Bredemeier, Markus.

Bredemeier M; Hospital Nossa Senhora da Conceição, Grupo Hospitalar Conceição, Porto Alegre, Brazil.

Arthritis Rheumatol ; 74(4): 733-734, 2022 04.

Article in English | MEDLINE | ID: covidwho-1772650

Subject(s)

Lung Diseases, Interstitial; Scleroderma, Systemic; Humans; Lung Diseases, Interstitial/drug therapy; Lung Diseases, Interstitial/etiology; Scleroderma, Systemic/complications; Scleroderma, Systemic/drug therapy; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Scleroderma, Systemic / Lung Diseases, Interstitial Topics: Long Covid Limits: Humans Country/Region as subject: North America Language: English Journal: Arthritis Rheumatol Year: 2022 Document Type: Article Affiliation country: Art.41993

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google